Aribio has completed the first tranche of a strategic equity investment agreement worth 42.5 billion won (approximately $31.5 million) with China's Puxing Pharmaceutical, totaling 11.475 billion won. Following a 7 trillion won technology export contract, this investment is expected to accelerate the global commercialization of the Alzheimer's treatment drug 'AR1001'.
On October 22, Aribio announced the completion of the first investment payment for a third-party allocation of new shares to Puxing Pharmaceutical. The two companies signed a strategic equity investment agreement in July, valued at $27.5 million (about 42.5 billion won), with this payment representing the first portion of the total investment.
Once the second investment is finalized, Puxing Pharmaceutical will hold approximately 5% of Aribio's shares, becoming the third-largest shareholder after Aribio Holdings and Samjin Pharmaceutical.
The investment was made following the Chinese government's approval of overseas direct investment (ODI) and remittance procedures, which caused a slight delay in the timeline.
Previously, Puxing Pharmaceutical entered into a global exclusive licensing agreement with Aribio for AR1001, valued at 7 trillion won. The completion of this equity investment further solidifies the partnership between the two companies.
Aribio plans to use the investment funds to prepare for the global commercialization of AR1001 and to develop subsequent pipeline projects. Key investment targets include global clinical trials for AR1005 and the electronic drug 'Herzion'.
Jae-jun Jeong, CEO of Aribio, stated, "Puxing Pharmaceutical's investment has strengthened our financial foundation and global partnerships. We will continue to advance the global development and commercialization of AR1001, as well as the development of our subsequent pipeline projects."
Additionally, Aribio is set to present the topline results of the global Phase 3 clinical trial 'POLARIS-AD' for AR1001 at the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference in Boston on November 16. Following the results, the company plans to engage with the U.S. Food and Drug Administration (FDA) regarding a New Drug Application (NDA). Aribio aims to achieve sales of 1 trillion won by 2030 through the commercialization and expansion of indications for AR1001.
On October 22, Aribio announced the completion of the first investment payment for a third-party allocation of new shares to Puxing Pharmaceutical. The two companies signed a strategic equity investment agreement in July, valued at $27.5 million (about 42.5 billion won), with this payment representing the first portion of the total investment.
Once the second investment is finalized, Puxing Pharmaceutical will hold approximately 5% of Aribio's shares, becoming the third-largest shareholder after Aribio Holdings and Samjin Pharmaceutical.
The investment was made following the Chinese government's approval of overseas direct investment (ODI) and remittance procedures, which caused a slight delay in the timeline.
Previously, Puxing Pharmaceutical entered into a global exclusive licensing agreement with Aribio for AR1001, valued at 7 trillion won. The completion of this equity investment further solidifies the partnership between the two companies.
Aribio plans to use the investment funds to prepare for the global commercialization of AR1001 and to develop subsequent pipeline projects. Key investment targets include global clinical trials for AR1005 and the electronic drug 'Herzion'.
Jae-jun Jeong, CEO of Aribio, stated, "Puxing Pharmaceutical's investment has strengthened our financial foundation and global partnerships. We will continue to advance the global development and commercialization of AR1001, as well as the development of our subsequent pipeline projects."
Additionally, Aribio is set to present the topline results of the global Phase 3 clinical trial 'POLARIS-AD' for AR1001 at the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference in Boston on November 16. Following the results, the company plans to engage with the U.S. Food and Drug Administration (FDA) regarding a New Drug Application (NDA). Aribio aims to achieve sales of 1 trillion won by 2030 through the commercialization and expansion of indications for AR1001.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.